4-(2,2-二乙氧基乙氧基)苯甲醛 | 82964-41-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2,2-二乙氧基乙氧基)苯甲醛
• 英文名称: 4-(2,2-diethoxyethoxy)benzaldehyde
• CAS: 82964-41-8
• 化学式: C₁₃H₁₈O₄
• 分子量: 238.284
• InChiKey: NOCGFCIGGIFIBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2,2-二乙氧基乙氧基)苯甲醛 在 palladium on activated charcoal 哌啶 、 polyphosphonate ethyl ester 、 氢气 、 苯甲酸 作用下， 以 1,4-二氧六环 、 氯仿 、 甲苯 为溶剂， 反应 65.0h， 生成 5-[4-[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione
  参考文献：
  名称：

  Dual PPAR-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential

  摘要：

  2,4-Thiazolidinedione derivatives of 1,3-benzoxazinone were synthesized and evaluated for their PPAR-alpha and gamma dual activation. DRF-2519, a compound obtained through SAR of TZD derivatives of benzoxazinone, has shown potent dual PPAR activation. In ob/ob mice, it showed better efficacy than the comparator molecules. In fat fed rat model, it showed significant improvement in lipid parameters, which was better than fibrates. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.08.043
• 作为产物：
  描述：

  对羟基苯甲醛 、 2-溴-1,1-二乙氧基乙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以58%的产率得到4-(2,2-二乙氧基乙氧基)苯甲醛
  参考文献：
  名称：

  1,3-二甲基巴比妥酸和乙烯基硫醚的5-亚芳基衍生物的生物正交杂狄尔斯-阿尔德环加成在活细胞内成像中的应用

  摘要：

  1,3-二甲基巴比妥酸的 5-亚芳基衍生物作为 1-氧杂-1,3-丁二烯和乙烯基硫醚作为亲二烯体的新生物正交环加成已应用于活细胞内成像。该反应在水介质中产率高、选择性强且快速。所提出的 1-oxa-1,3-丁二烯衍生物与 FITC 荧光染料缀合，可选择性地快速标记用亲二烯体紫杉醇预处理的癌细胞。各种提出的生物正交环加成的二阶速率常数k 2估计在 0.9 × 10 -2 M -1 s -1到 1.4 M -1 s -1的范围内，这比第一代 TQ 连接（邻喹啉酮醌甲基化物和乙烯基硫醚连接， k 2 = 1.5 × 10 −3 M −1 s −1 ）与第二代 TQ 连接相当或更好（ k 2 = 2.8 × 10 -2 M -1 s -1 )。所提出的连接反应的反应速率常数k 2在四嗪和降冰片烯或四嗪和环丙烯的速率常数k 2的范围内。 这些发现表明该化学物质适用于体外成像实验。

  DOI：

  10.1039/d1ob00697e

文献信息

• Benzothiazin and benzoxazin derivatives; their preparation and uses
  申请人：Dr. Reddy's Research Foundation

  公开号：US06130214A1

  公开（公告）日：2000-10-10

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. ##STR1##

  本发明涉及新型抗肥胖和降胆固醇化合物，它们的衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地说，本发明涉及一般式（I）的新型β-芳基-α-氧基取代烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。
• Synthesis, photochemistry and cross-linking of visibly sensitised photopolymers of PVA based on (E)-2-(4-Formylstyryl)-3,4-dimethylthiazolium Methylsulfate
  作者：Ian C. Barker、Norman S. Allen、Michele Edge、John A. Sperry、Richard J. Batten

  DOI：10.1039/ft9949003677

  日期：——

  The synthesis and cross-linking of new, visibly sensitive high-speed water-soluble photoresists are reported. Attempts to sensitise our existing poly(vinyl alcohol)(PVA)-based photopolymer into the visible region with various additives at between 1 and 5 mol% have been unsuccessful. The additives may disrupt the formation or configuration of the dimeric aggregates previously found to be a prerequisite for cross-linking or have a screening effect absorbing some or all of the photonic energy, thereby preventing excitation of any aggregated chromophore groups.Synthetic modification of the original (E)-2-(4-formylstyryl)-3,4-dimethylthiazolium methylsulfate produces chromophores which, when grafted onto PVA, generate photopolymers absorbing in the visible region. (E)-2-[4-(2-Ethylbutoxy)-styryl]-3-methylbenzothiazolium methylsulfate forms a photopolymer with λmax at 400 nm; while (E)-2-[2-(2,2-diethoxyethoxy)-4-(N,N-diethylamino)styryl]-3,4-dimethylthiazolium methylsulfate forms a photopolymer with λmax at 495 nm. Step-wedge analysis, UV absorption and FT-NMR spectroscopy indicate that the thiazolium and benzothiazolium photopolymers cross-link by a [2 + 2]cycloaddition reaction generating interchain cross-links via cyclobutane units. However, the amine photopolymer does not show any evidence of cross-linking, with the stencil being completely washed out during step-wedge analysis. Molecular modelling indicates that the diethoxyethoxy group prevents formation of the aggregates normally formed by electrostatic attractions.This theoretical prediction is confirmed by fluorescence spectroscopy. In high-concentration solutions the thiazolium and benzothiazolium models show significant emission bands relating to excimer or higher-order aggregate species. Upon dilution these bands are blue shifted to wavelengths comparable to those observed for photopolymer films. At very dilute concentrations they are lost and monomer bands appear while for thin films they are lost upon dimerisation. The amine photopolymer shows very weak emission bands unaffected upon exposure. This confirms that very few aggregates are formed, suggesting they are in non-reactive configurations.

  本报告介绍了新型可见光敏感高速水溶性光致抗蚀剂的合成和交联过程。我们曾尝试使用各种添加剂将现有的聚乙烯醇（PVA）光聚合物敏化到可见光区域，添加剂的浓度在 1 至 5 摩尔% 之间，但都没有成功。添加剂可能会破坏二聚体的形成或构型，而以前发现二聚体是交联的先决条件，或者添加剂会产生屏蔽效应，吸收部分或全部光子能量，从而阻止任何聚合的发色团基团被激发。对原始的(E)-2-(4-甲酰基苯乙烯基)-3,4-二甲基噻唑鎓甲硫酸盐进行合成改性可产生发色团，当这些发色团接枝到 PVA 上时，可产生在可见光区域具有吸收性的光聚合物。(E)-2-[4-(2-乙基丁氧基)-苯乙烯基]-3-甲基苯并噻唑鎓甲硫酸盐形成的光聚合物的 λmax 波长为 400 纳米；而(E)-2-[2-(2,2-二乙氧基乙氧基)-4-(N,N-二乙基氨基)苯乙烯基]-3,4-二甲基噻唑鎓甲硫酸盐形成的光聚合物的 λmax 波长为 495 纳米。阶跃对冲分析、紫外吸收和傅立叶变换-核磁共振光谱表明，噻唑鎓和苯并噻唑鎓光聚合物通过环丁烷单元发生[2 + 2]环加成反应，产生链间交联。然而，胺类光聚合物没有显示出任何交联迹象，在阶跃分析过程中，模板被完全洗掉。分子建模表明，二乙氧基乙氧基基团阻止了通常由静电吸引形成的聚集体的形成。在高浓度溶液中，噻唑鎓和苯并噻唑鎓模型显示出与准分子或高阶聚集体物种有关的显著发射带。稀释后，这些波段会蓝移，波长与光聚合物薄膜的波长相当。在浓度非常稀的情况下，这些条带会消失，并出现单体条带，而在薄膜中，这些条带会在二聚化时消失。胺类光聚合物在曝光后会出现非常微弱的发射带，不受影响。这证明形成的聚集体非常少，表明它们处于非反应构型。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVELLES COMPOSITIONS HETEROCYCLIQUES ET LEUR UTILISATION EN MEDECINE; PROCEDES DE LEUR FABRICATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1999016758A1

  公开（公告）日：1999-04-08

  (EN) The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel $g(b)-aryl-$g(a)-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.(FR) La présente invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant. Plus particulièrement, cette invention se rapporte à de nouveaux acides alkylcarboxyliques $g(b)-aryl-$g(a)-oxysubstitués qui correspondent à la formule générale (I), ainsi qu'à leurs dérivés, analogues, formes tautomères, stéréoisomères, polymorphes, sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables et à des compositions pharmaceutiquement acceptables les contenant.

  本发明涉及新型抗肥胖和降低胆固醇化合物，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。更具体地说，本发明涉及一般式（I）的新型$g(b)-芳基-$g(a)-氧基取代的烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂化物和包含它们的药学上可接受的组合物。
• 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
  申请人：Wyeth

  公开号：US20020169325A1

  公开（公告）日：2002-11-14

  This invention provides compounds of Formula I having the structure 1 wherein: A, X, Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供了具有结构1的化合物，其公式为： 其中，A、X、Y、Z、R1、R2、R3、R4、R5和R6如前所定义，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐症相关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC.

  公开号：US20010027198A1

  公开（公告）日：2001-10-04

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (1), their derivatives, their analogs, their tautomeric forms, their stereosomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1 The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.

  本发明涉及新型抗肥胖和降胆固醇化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。更具体地，本发明涉及一般式（1）的新型β-芳基-α-氧基取代烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂及含有它们的药学上可接受的组合物。本发明还涉及制备上述新型化合物、类似物、衍生物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂、新型中间体和含有它们的制药组合物的方法。